Spots Global Cancer Trial Database for Sarcopenia in Head and Neck Cancer Patients Treated With Curative Hadrontherapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sarcopenia in Head and Neck Cancer Patients Treated With Curative Hadrontherapy

Official Title: Role of Baseline Sarcopenia in Determining Acute Toxicity for Head and Neck Cancer Patients Treated With Curative Hadrontherapy: a Prospective Monoinstitutional Study

Study ID: NCT06207708

Conditions

Head and Neck Cancer

Interventions

questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement

blood biomarkers

Study Description

Brief Summary: The study focuses on the impact of sarcopenia on acute and late toxicities in head and neck tumor affected patients treated with particle therapy.

Detailed Description: To evaluate in HNC patients treated with particle therapy the impact of SP (measured by low skeletal muscle mass at the C3 vertebral body) on toxicity profile assessed according to NCI's Common Terminology Criteria for Adverse Events CTCAE (version 5.0), defined as: * Acute toxicity: within 3 months from the beginning of particle RT * Late toxicity: more than 6 months after the end of particle RT. To investigate possible association between SP and nutritional